Scarica l'app Stockscreener
20.81
2.30%
-0.49
Dopo l'orario di chiusura:
20.81
Precedente Chiudi:
$21.30
Aprire:
$21.16
Volume 24 ore:
90,314
Relative Volume:
0.46
Capitalizzazione di mercato:
$712.23M
Reddito:
-
Utile/perdita netta:
$-81.05M
Rapporto P/E:
-7.9331
EPS:
-2.6232
Flusso di cassa netto:
$-68.97M
1 W Prestazione:
-0.53%
1M Prestazione:
+26.74%
6M Prestazione:
-34.93%
1 anno Prestazione:
+20.78%
Intervallo 1D:
$20.66
$21.42
Intervallo di 1 settimana:
$19.48
$21.79
Portata 52W:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Nome
Arrivent Biopharma Inc
Settore
Industria
Telefono
240-780-6356
Indirizzo
18 CAMPUS BLVD., NEWTOWN SQUARE
Confronta AVBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
20.81 | 712.23M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-20 | Iniziato | B. Riley Securities | Buy |
| 2025-03-10 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-20 | Iniziato | Citigroup | Buy |
| 2024-02-20 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | Jefferies | Buy |
Mostra tutto
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Wells Fargo & Company MN - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down – Here’s Why - Defense World
Barclays PLC Grows Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Invesco Ltd. Takes Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by JPMorgan Chase & Co. - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update - Defense World
Legal & General Group Plc Purchases 10,783 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Appoints Dr. Merdad Parsey to Board of Directors - MyChesCo
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - The Manila Times
ArriVent BioPharma appoints new board member By Investing.com - Investing.com South Africa
ArriVent BioPharma appoints new board member - Investing.com Australia
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - citybiz
ArriVent BioPharma (AVBP) Strengthens Leadership with New Board Appointment | AVBP Stock News - GuruFocus
Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress - MyChesCo
Learn to Evaluate (AVBP) using the Charts - news.stocktradersdaily.com
Geode Capital Management LLC Cuts Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
In Depth: Popular Overseas Expansion Strategy Holds Pitfalls for Chinese Drug Developers - Caixin Global
Vanguard Group Inc. Has $37.76 Million Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
41,921 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Wellington Management Group LLP - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Buy” by Brokerages - Defense World
KLP Kapitalforvaltning AS Purchases New Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Corebridge Financial Inc. Has $373,000 Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
(AVBP) Trading Report - news.stocktradersdaily.com
Swiss National Bank Buys Shares of 26,400 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MyChesCo
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MyChesCo
Charles Schwab Investment Management Inc. Has $5.50 Million Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (AVBP) Projected to Post Earnings on Thursday - The AM Reporter
Brokers Offer Predictions for AVBP Q1 Earnings - Defense World
Brokerages Set ArriVent BioPharma, Inc. (NASDAQ:AVBP) Target Price at $39.40 - Defense World
B. Riley Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at B. Riley - Defense World
B.Riley sets $37 target on ArriVent stock, initiates with Buy - Investing.com Canada
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside - Benzinga
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
B. Riley Initiates ArriVent BioPharma at Buy With $37 Price Target -March 20, 2025 at 07:13 am EDT - MarketScreener
ArriVent Biopharma initiated with a Buy at B. Riley - TipRanks
ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Thursday - Defense World
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
ArriVent BioPharma reports FY results - MSN
Taiho Expands Cancer Pipeline With ADCs In $400m Araris Buy - insights.citeline.com
(AVBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
ArriVent BioPharma appoints PwC as new auditor - Investing.com India
ArriVent BioPharma appoints PwC as new auditor By Investing.com - Investing.com South Africa
ArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at Guggenheim - Defense World
Oppenheimer starts ArriVent BioPharma at outperform - MSN
Guggenheim starts ArriVent Biopharma with a Buy on firmonertinib potential - TipRanks
Financial Contrast: ArriVent BioPharma (AVBP) and The Competition - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Earns “Buy” Rating from HC Wainwright - Defense World
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength - MSN
Arrivent Biopharma Inc Azioni (AVBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):